Firstly, no significant alteration was found on the expression of cyclin A/D1/E and Cdc25A in both NSCLC cell lines under the treatments with Rapamycin or Dasatinib (S2 Fig). This evidence concerns the gene CCNA2 and non-small cell lung carcinoma.